Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.
Press releases published on April 10, 2025

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, …

Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ace Vision Group, Inc. (“AVG” or “the Company”), an emerging medical device company on the forefront of pioneering a laser microporation therapy for the aging eye, today announced that it will host an event and …

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX …

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new studies of NUZYRA® …

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website …

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy …

CRB Named Rockwell Automation EPC Partner of the Year
Kansas City, Missouri, April 10, 2025 (GLOBE NEWSWIRE) -- CRB, a leading provider of engineering, architecture, construction, consulting solutions, and control systems integration is honored to be recognized as the Rockwell Automation Engineering, …

Large Reductions in Suicide Risk, Attempts and Deaths Demonstrated by Three “Real World” Studies in Primary Care
NORWALK, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- The suicide rate in the US was at a more than 80-year high in 2022 with a leveling at this higher rate in the past three years. And a large majority of patients who die by suicide have visited a primary …

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT’s) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “ …

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has …

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication …

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, …

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and …

Dr. Mahmoud Aljurf, First Non-US Physician to win Weinberger Prize by American College of Physicians
RIYADH, Saudi Arabia, April 10, 2025 (GLOBE NEWSWIRE) -- Dr. Mahmoud Aljurf, M.D., MACP, Director of the Adult Stem Cell Transplantation and Cellular Therapy Program King Faisal Specialist Hospital …

Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics has named Roger Ilagan, PhD as its new Chief Scientific Officer (CSO). Responsible for guiding the biologic drug development of first-in-class wound care technology that …

The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 10 APRIL 2025 at 13.15 EEST The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a …

Helsingin hovioikeus tuomitsi Orionin hallituksen jäsenen sakkorangaistukseen arvopaperimarkkinoita koskevasta tiedottamisrikoksesta
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 10.4.2025 KLO 13.15 Helsingin hovioikeus tuomitsi Orionin hallituksen jäsenen sakkorangaistukseen arvopaperimarkkinoita koskevasta …

Keros Therapeutics Announces Review of Strategic Alternatives
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on …

Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and …

Neue Imprivata Studie: Mehr als die Hälfte aller befragten deutschen Unternehmen von Cybervorfällen aus der Lieferkette betroffen
LANGENFELD, Deutschland, April 10, 2025 (GLOBE NEWSWIRE) -- Eine Studie des Ponemon Institutes gemeinsam mit Imprivata ergab, dass 51 Prozent der befragten deutschen Unternehmen einen Datenverlust oder eine Cyberattacke als Folge eines …